8-K
filed July 3, 2024, 7:59 PM ET
ticker SKYE
CIK 0001516551
leadership
confidence high
sentiment neutral
materiality 0.60
Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1
Skye Bioscience, Inc.
- Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.
- Drs. Keith Ward and Praveen Tyle resign from board effective Aug 1, 2024; no disagreement with company.
- Grants new General Counsel Brennen Brodersen inducement award: option for 60,000 shares and 15,000 RSUs.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Ward, PhD resigned as Director at Skye Bioscience, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Karen L. Smith MD, PhD, MBA, LLM was appointed as Director at Skye Bioscience, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Praveen Tyle, PhD resigned as Director at Skye Bioscience, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.